Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
Phase 2
Completed
NCT03364153
| Condition | Stargardt's Macular Dystrophy |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Astellas Pharma Global Development, Inc. |
|---|
| Status | Completed |
|---|
| Enrollment | 121 participants |
|---|
| Interventions | avacincaptad pegol, Sham |
|---|
| Start date | Jan 12, 2018 |
|---|
| Completion date | Mar 31, 2025 |
|---|
| Results posted | Mar 12, 2026 |
|---|
Summary
The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
Mean Rate of Change in the Area of Ellipsoid Zone Defect From Baseline Through Month 18
Baseline to Month 18 · mm^2/18 months
| Avacincaptad Pegol | 0.6383 ± 0.1113 mm^2/18 months |
|---|
| Sham | 0.6644 ± 0.1081 mm^2/18 months |
|---|
| p-value | 0.8669 |
|---|
| difference in LS mean | -0.0261 (95% CI -0.3334–0.2813) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.